Background: Developmental disorders are associated with microglial dysfunction. Oral administration of lipopolysaccharide derived from Pantoea agglomerans bacteria (LPSp) leads to normalization of phagocytic activity of microglia and suppression of inflammation in mice. In this article, we report on a successful trial in which we achieved a significant improvement of symptoms in patients with developmental disorders. Patients and Methods: Five pediatric patients diagnosed with autism spectrum disorders (ASD)/attention deficit hyperactivity disorder (ADHD) who visited our clinic received either 0.75 or 1 mg/day LPSp for 6 months or more, in addition to our usual therapy regimens (detoxification therapy, nutritional therapy, and vibration therapy). A survey questionnaire was completed by the patients' parents and evaluated using the Numerical Rating Scale. Results: Behavior, verbal ability, and communication disabilities associated with ASD/ADHD improved in all patients. Conclusion: Oral administration of LPSp may represent a new treatment option in the area of developmental disorders where there is currently no treatment available.Developmental disorders result from a set of disabilities in body, learning, language, or behavioral fields (1). Typical developmental disorders include autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), learning disabilities, and other similar disorders of brain function (1). These symptoms usually appear at a young age. Although 10% of cases have a genetic background, the underlying etiology is unknown in most patients (2). These conditions begin during development and can adversely affect daily life. Developmental disorders rarely resolve and usually last a lifetime (1).ASD is a neurodevelopmental disorder characterized by social and communication difficulties and rigid repetitive behaviors. Another neurodevelopmental disorder, ADHD, is characterized by excessive activity and impulsiveness inappropriate to the patient's age, as well as inattention, hyperactivity, and impulsivity (1). The prevalence of these two disorders is high, with recent reports showing that ASD occurs in 1.5% of the population and ADHD in 7.2% (3)(4). Studies also show that the incidence of ASD in boys is 3-4 times that in girls (5).Treatment of ASD mainly follows the recommendations of the British Autism Society's "SPELL (Structure, Positive, Empathy, Low Arousal, Links)" philosophy, however, suitable pharmacotherapy has not yet been developed because the cause and nature of the condition are as yet unknown (6). Treatment of ADHD mainly includes nursing and pharmacotherapy. ADHD treatment focuses on improving symptoms through environmental adjustment, social life skills training, and parent training. Pharmacotherapy includes the use of central stimulants (methylphenidate) and noradrenaline reuptake inhibitors. As much as 41-78% of patients with ASD also have ADHD and when the two disorders are combined, the symptoms of autism (social disorders, impaired daily living functions) becom...